Table 3 Estimates of the causal effect of plasma uridine level on AF by four complementary methods.

From: Protective effect of uridine on atrial fibrillation: a Mendelian randomisation study

Data source

Method

OR

95% CI

p-value

GWAS meta-analysis (Nielsen et al.)

IVW (fixed-effects)

0.27

(0.12, 0.62)

2.20 × 10–03

Weighted median

0.23

(0.08, 0.65)

5.22 × 10–03

Simple median

0.22

(0.07, 0.64)

5.83 × 10–03

Simple mode

0.20

(0.06, 0.65)

0.115

AF HRC

IVW (fixed-effects)

0.26

(0.10, 0.65)

3.87 × 10–03

Weighted median

0.23

(0.07, 0.77)

0.018

Simple median

0.22

(0.06, 0.75)

0.016

Simple mode

0.18

(0.04, 0.91)

0.173

FinnGen

IVW (fixed-effects)

0.61

(0.08, 4.52)

0.629

Weighted median

0.21

(0.01, 3.50)

0.276

Simple median

0.29

(0.01, 6.37)

0.435

Simple mode

0.13

(0.005, 3.4)

0.343

  1. AF HRC Atrial Fibrillation Haplotype Reference Consortium, SNPs single-nucleotide polymorphisms, IVW inverse-variance weighted, OR odds ratio, CI confidence interval.
Back to article page